The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine

Biotechnology and Bioengineering

Volumn 111, Issue 12, 2014, Pages 2398-2406

  Tyler, Mitchell ^a   Tumban, Ebenezer ^a   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Epitope; Human papillomavirus; Vaccines; Virus like particles; VLP vaccines

Indexed keywords

EPITOPES; ONCOGENIC VIRUSES; PEPTIDES; VACCINES;

ANTIBODY RESPONSE; ANTIGENIC VARIATION; CAPSID PROTEINS; CERVICAL CANCERS; HUMAN PAPILLOMAVIRUS; HYBRID PARTICLES; IMMUNOGENICITY; VIRUS-LIKE PARTICLES;

ANTIBODIES;

CAPSID PROTEIN; EPITOPE; WART VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENIC VARIATION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; VIRUS HYBRID; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; IMMUNOLOGY; VIRION;

HUMAN PAPILLOMAVIRUS; MIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; EPITOPES; FEMALE; MICE; MICE, INBRED BALB C; PAPILLOMAVIRUS VACCINES; VIRION;

EID: 84918820741     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25311     Document Type: Article

References (35)

1. Bachmann MF, Zinkernagel RM. 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol 15:235-270.
2. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78(2):751-757.
3. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2005a. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119:445-462.
4. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. 2005b. Maturation of papillomavirus capsids. J Virol 79(5):2839-2846.
5. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. 2011. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 10(11):1569-1583.
6. Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183-186.
7. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS. 2010. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28(27):4384-4393.
8. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. 1993. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74(Pt 6):945-953.
9. Chackerian B. 2007. Virus-like particles: Flexible platforms for vaccine development. Expert Rev Vaccines 6(3):381-390.
10. Chackerian B, Caldeira Jdo C, Peabody J, Peabody DS. 2011. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. J Mol Biol 409(2):225-237.
11. Chan TD, Brink R. 2012. Affinity-based selection and the germinal center response. Immunol Rev 247(1):11-23.
12. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. 1991. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181(2):572-579.
13. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. 2012. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 19(7):1075-1082.
14. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. 2007a. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81(21):11585-11592.
15. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. 2007b. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81(24):13927-13931.
16. Hunter Z, Tumban E, Dziduszko A, Chackerian B. 2011. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine 29(28):4584-4592.
17. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kundig T, Bachi T, Storni T, Jennings G, Pumpens P, et al. 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20(25-26):3104-3112.
18. Karanam B, Jagu S, Huh WK, Roden RB. 2009. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 87(4):287-299.
19. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89(24):12180-12184.
20. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13(1):89-99.
21. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. 1992. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187(2):612-619.
22. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. 2014. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111(3):425-440.
23. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. 2010. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102(5):325-339.
24. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Muller M, Kellner M, Horer M, et al. 2012. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS ONE 7(6):e39741.
25. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. 2005. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337(2):365-372.
26. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo, Caldeira J, Chackerian B. 2008. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 380(1):252-263.
27. Pumpens P, Grens E. 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44(2-3):98-114.
28. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13(7):857-861.
29. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. 2000. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270(2):254-257.
30. Rose RC, Bonnez W, Reichman RC, Garcea RL. 1993. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles. J Virol 67(4):1936-1944.
31. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. 2013. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 133(12):2706-2713.
32. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, Milich D. 1994. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 180(3):1037-1046.
33. Stanley M. 2010. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117(2 suppl.):S5-S10.
34. Tumban E, Peabody J, Peabody DS, Chackerian B. 2011. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE 6(8):e23310.
35. Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. 2012. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS ONE 7(11):e49751.